Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Susan B. Laffan"'
Autor:
Susan B Laffan, Andrew S Thomson, Shing Mai, Cindy Fishman, Takahito Kambara, Kiran Nistala, James T Raymond, Shugui Chen, Thulasi Ramani, Laura Pageon, Rodd Polsky, Mark Watkins, Gemma Ottolangui, John R White, Curtis Maier, Michael Herdman, Gerben Bouma
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0231655 (2020)
Despite the potential for the chemokine class as therapeutic targets in immune mediated disease, success has been limited. Many chemokines can bind to multiple receptors and many receptors have multiple ligands, with few exceptions. One of those exce
Externí odkaz:
https://doaj.org/article/ee33790a5c0946eb8e5ea303f460bcc0
Autor:
Cindy Fishman, Jessica M. Caverly Rae, Lorraine M. Posobiec, Susan B. Laffan, Steven A. Lerman, Neil Pearson, Salim Janmohamed, Etienne Dumont, Deatra Nunn-Floyd, Dinesh J. Stanislaus
Publikováno v:
Antimicrobial agents and chemotherapy. 66(11)
Fluoroquinolone use in children is limited due to its potential toxicity and negative effects on skeletal development, but the actual effects/risks of fluoroquinolones on bone growth and the mechanisms behind fluoroquinolone-driven arthropathy remain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::129799bcdac6a1851ef2d41840cd555f
https://pubmed.ncbi.nlm.nih.gov/36255258
https://pubmed.ncbi.nlm.nih.gov/36255258
Autor:
Lorraine M. Posobiec, Susan B. Laffan
Publikováno v:
Birth defects researchREFERENCES. 113(5)
Objectives Strategies for conducting juvenile dose ranging studies before definitive toxicity juvenile animal studies (JAS) have evolved, but the aim of demonstrating study design robustness and efficient animal use remains the same. The objective of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc6fa6abfcb461999ea8af0b8ca37507
https://pubmed.ncbi.nlm.nih.gov/33314670
https://pubmed.ncbi.nlm.nih.gov/33314670
Autor:
Helen F. Sneddon, Rodolfo Cadilla, Young Do, Jeffrey Guss, Gordon Saxty, Paresh I. Masuria, Caterina Musetti, J. Darren Stuart, Beth Pietrak, Daniela Ennulat, Andrew G. King, Barry G. Shearer, Nicholas J. Kramer, Peckham Gregory, Chuck Poole, Alan R. Rendina, Daniel J. Price, H. Fritz Kramer, Tiahshun Xu, Girish Sati, Stephen A. Thomson, Patricia A. Elkins, Jason A. Holt, Alan V. McDougal, Joseph W. Wilson, Susan B. Laffan, Michael R. Jeune, Jan Klapwijk, Dean N. Thomas, Mark Youngman, Paris Ward, Paul N. Mortenson, Lisa M. Shewchuk, Eugene L. Stewart, David N. Deaton
Publikováno v:
Bioorganicmedicinal chemistry. 28(23)
GlaxoSmithKline and Astex Pharmaceuticals recently disclosed the discovery of the potent H-PGDS inhibitor GSK2894631A 1a (IC50 = 9.9 nM) as part of a fragment-based drug discovery collaboration with Astex Pharmaceuticals. This molecule exhibited good
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0464fe491c8ae02c9501daac98d3f990
https://pubmed.ncbi.nlm.nih.gov/33059303
https://pubmed.ncbi.nlm.nih.gov/33059303
Autor:
Gemma Ottolangui, Curtis Maier, Shugui Chen, James T. Raymond, Rodd Polsky, Cindy E. Fishman, Michael Herdman, Takahito Kambara, John R. White, Thulasi Ramani, Laura Pageon, Susan B. Laffan, Shing Mai, Kiran Nistala, Andrew S. Thomson, Gerben Bouma, Mark S Watkins
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 4, p e0231655 (2020)
PLoS ONE, Vol 15, Iss 4, p e0231655 (2020)
Despite the potential for the chemokine class as therapeutic targets in immune mediated disease, success has been limited. Many chemokines can bind to multiple receptors and many receptors have multiple ligands, with few exceptions. One of those exce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44d6ffd7d2872d680d4c786594a745e5
http://europepmc.org/articles/PMC7180069
http://europepmc.org/articles/PMC7180069
Autor:
Mary K. Ziejewski, Dinesh Stanislaus, Howard M. Solomon, Elizabeth H. Romach, Susan B. Laffan, Lorraine M. Posobiec
Publikováno v:
Birth defects researchREFERENCES. 112(3)
The success of new antiretroviral medicines for HIV resulted in a change to guidelines of standard therapy where continuation of antiretroviral therapy is recommended to maintain the low viral load during pregnancy, thereby preventing transmission of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f5908ffb260f3092e077c0549c02b06
https://pubmed.ncbi.nlm.nih.gov/31859466
https://pubmed.ncbi.nlm.nih.gov/31859466
Publikováno v:
Birth Defects Research Part B: Developmental and Reproductive Toxicology. 104:244-252
Dabrafenib (DAB), an inhibitor of BRAF kinase activity, is approved for metastatic melanoma with a BRAF V600E mutation. In support of pediatric cancer development, a nonclinical juvenile rat toxicity study was conducted in which females had early vag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a7e4dcf91b66665c8b704d8e9e0b93c
https://doi.org/10.1002/bdrb.21165
https://doi.org/10.1002/bdrb.21165
Publikováno v:
Birth defects research. 110(3)
The postnatal development of the female reproductive system in laboratory animals and humans is reviewed. To enable a meaningful species comparison of the developing female reproductive system, common definitions of developmental processes were estab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::eebe45e924dc4a09797b1d93336bba36
https://pubmed.ncbi.nlm.nih.gov/29243395
https://pubmed.ncbi.nlm.nih.gov/29243395
Autor:
Tacey E. K. White, Robert L. Clark, Kai‐fen Wang, Paul B. Bushdid, Lorraine M. Posobiec, Susan B. Laffan
Publikováno v:
Birth Defects Research Part B: Developmental and Reproductive Toxicology. 98:445-458
Within 24 hr after oral administration of the antimalarial artesunate to rats on Day 10 or 11 postcoitum (pc), there is depletion of embryonic erythroblasts (EEbs), leading to embryo malformation and death. The proximate agent is dihydroartemisinin (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::678d3aa6cf3297e0ba0a26841ef18ab0
https://doi.org/10.1002/bdrb.21088
https://doi.org/10.1002/bdrb.21088
Autor:
Brian P. Enright, Zoltan Erdos, James H. Kim, Gerhard F. Weinbauer, David Potter, Michelle Coulson, Michael S. Thibodeau, Jeffrey S. Moffit, William J. Breslin, Susan B. Laffan, Manisha Sonee, Richard Goldstein, William J. Reagan, Louise Parks Saldutti, Robert E. Chapin
Publikováno v:
Birth Defects Research Part B: Developmental and Reproductive Toxicology. 98:110-118
The Developmental and Reproductive Toxicity Technical Committee of the Health and Environmental Sciences Institute hosted a working consortium of companies to evaluate a new commercially available analytic assay for Inhibin B in rat serum or plasma.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::668716fb6b87d4d15d1bead8fc7674c2
https://doi.org/10.1002/bdrb.21041
https://doi.org/10.1002/bdrb.21041